Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS; CASCADE Collaboration..

Lancet. 2003 Oct 18;362(9392):1267-74.

PMID:
14575971
3.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study..

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
4.

Determinants of progression to AIDS and death following HIV diagnosis: a retrospective cohort study in Wuhan, China.

Jiang H, Xie N, Cao B, Tan L, Fan Y, Zhang F, Yao Z, Liu L, Nie S.

PLoS One. 2013 Dec 23;8(12):e83078. doi: 10.1371/journal.pone.0083078.

5.

Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration..

Am J Epidemiol. 2008 Sep 1;168(5):532-40. doi: 10.1093/aje/kwn179.

PMID:
18663213
7.

Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category.

Pérez-Hoyos S, del Amo J, Muga R, del Romero J, García de Olalla P, Guerrero R, Hernàndez-Aguado I; GEMES (Spanish Multicenter Study Group of Seroconverters)..

AIDS. 2003 Feb 14;17(3):353-9.

PMID:
12556689
8.

A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival.

Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD.

J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

PMID:
10634199
9.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration..

HIV Med. 2000 Oct;1(4):224-31.

10.

Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men.

Prins M, Sabin CA, Lee CA, Devereux H, Coutinho RA.

AIDS. 2000 Aug 18;14(12):1829-37.

PMID:
10985321
11.

Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.

Sánchez JM, Ramos Amador JT, Fernández de Miguel S, González Tomée MI, Rojo Conejo P, Ferrnado Vivas P, Clemente Vivas J, Ruiz Contreras J, Nogales Espert A.

Pediatr Infect Dis J. 2003 Oct;22(10):863-7.

PMID:
14551485
12.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
13.

Geographical variation in disease progression in HIV-1 seroconverted injecting drug users in Europe?

Prins M, Brettle RP, Robertson JR, Hernández Aguado I, Broers B, Carré N, Goldberg DJ, Zangerle R, Coutinho RA, van den Hoek A.

Int J Epidemiol. 1999 Jun;28(3):541-9.

PMID:
10405862
14.

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, Prins M; CASCADE Collaboration..

AIDS. 2006 Mar 21;20(5):741-9.

PMID:
16514305
15.

Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.

García de la Hera M, Ferreros I, del Amo J, García de Olalla P, Pérez Hoyos S, Muga R, del Romero J, Guerrero R, Hernández-Aguado I; GEMES..

J Epidemiol Community Health. 2004 Nov;58(11):944-50.

16.

[Socio-demographic factors associated with the progression of HIV infection and the impact of HAART in a seroconverter cohort in Madrid (1986-2009)].

Monge S, Del Romero J, Rodríguez C, de Mendoza C, de Górgolas M, Cosín J, Dronda F, Pérez-Cecilia E, Peña JM, Santos I, Rubio R, Del Amo J; Grupo de Seroconvertores de la Comunidad de Madrid..

Enferm Infecc Microbiol Clin. 2012 Mar;30(3):117-23. doi: 10.1016/j.eimc.2011.07.016. Spanish.

PMID:
22014512
17.

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.

Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G.

AIDS. 1997 Mar 15;11(4):461-7.

PMID:
9084793
18.

Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.

Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K; CASCADE Collaboration..

Ann Neurol. 2008 Feb;63(2):213-21.

PMID:
17894380
20.

Survival following HIV infection of a cohort followed up from seroconversion in the UK.

Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, Phillips A, Porter K; UK Register of HIV Seroconverters..

AIDS. 2008 Jan 2;22(1):89-95.

PMID:
18090396

Supplemental Content

Support Center